



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



AZD 7325

Item No. 36449

CAS Registry No.: 942437-37-8
Formal Name: 4-amino-8-(2-fluoro-6-methoxyphenyl)-N-propyl-3-cinnolinecarboxamide
Synonym: BAER-101
MF: C₁₉H₁₉FN₄O₂
FW: 354.4
Purity: ≥98%
UV/Vis.: λ_{max}: 220, 345 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

AZD 7325 is supplied as a solid. A stock solution may be made by dissolving the AZD 7325 in the solvent of choice, which should be purged with an inert gas. AZD 7325 is soluble in DMSO.

Description

AZD 7325 is a positive allosteric modulator of α_2 - and α_3 subunit-containing GABA_A receptors and a neutral antagonist for α_1 subunit-containing GABA_A receptors.¹ It binds to GABA_A receptors in membranes from Sf9 cells expressing $\alpha_2\beta_3\gamma_2$ subunit-containing receptors ($K_i = 0.309$ nM). AZD 7325 (1 mg/kg) increases marble-burying behavior, indicating anxiety-like activity, and decreases audiogenic seizure severity in the *Fmr1*^{-/-} mouse model of fragile X syndrome.²

References

- Alhambra, C., Becker, C., Blake, T.A., *et al.* Development and SAR of functionally selective allosteric modulators of GABA_A receptors. *Bioorg. Med. Chem.* **19(9)**, 2927-2938 (2011).
- Schaefer, T.L., Ashworth, A.A., Tiwari, D., *et al.* GABA_A alpha 2,3 modulation improves select phenotypes in a mouse model of fragile X syndrome. *Front. Psychiatry* **12**, 678090 (2021).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/19/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM